Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ocala Oncology Center

Neither a doctor nor a teaching hospital

Research payments

$741,028

136 payments

Through program year 2025, Ocala Oncology Center is reported as receiving $741,028 in research payments, across 136 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $223,578 18
2024 Research $354,452 28
2023 Research $50,624 29
2022 Research $60,110 42
2021 Research $20,296 4
2020 Research $20,113 4
2019 Research $11,855 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $436,720 2 payments
  2. Sobi, Inc $116,644 72 payments
  3. Epizyme, Inc., $94,480 37 payments
  4. Incyte Corporation $36,032 10 payments
  5. Celgene Corporation $33,240 2 payments
  6. Amgen Inc. $15,895 3 payments
  7. AstraZeneca Pharmaceuticals LP $3,640 1 payment
  8. Allergan Inc. $3,331 7 payments
  9. Seattle Genetics, Inc. $956 1 payment
  10. E.R. Squibb & Sons, L.L.C. $89 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. An Open-Label Phase 1a,1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors $279,120 1 payment
  2. An Open-Label Phase 1a,1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors $157,600 1 payment
  3. Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma $94,480 37 payments
  4. Ava-Itp-401 $88,564 52 payments
  5. A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) $33,240 2 payments
  6. Prospective, Multi-Center, Open-Label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (Itp) After Switching to Avatrombopag From Eltrombopag Or Romiplostim $28,080 20 payments
  7. LCM: A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 2 $14,795 2 payments
  8. A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208) $14,250 2 payments
  9. Prospective, Non Interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic Or Community Clinical Practices $13,069 5 payments
  10. Evaluation of Ruxolitinib and Azacytidine Combination As A Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome Myeloproliferative Neoplasm $8,713 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record